Feasibility Study of ExAblate Thalamotomy for Treatment of Chronic Trigeminal Neuropathic Pain

Inclusion Criteria: * Men and women, between 18 and 75 years, inclusive * Subjects who are able and willing to give consent and able to attend all study visits * Severe chronic, trigeminal neuropathic pain of ≥6 months duration. * Pain is medication-refractory to adequate trials of at least 3 prescription medications commonly used for symptomatic relief of neuropathic pain with current adjunctive use of at least one medication. An adequate medication trial is defined as a therapeutic dose of each medication without sufficient effect. * Pain is treatment-resistant to at least one interventional therapies including injections, procedures, neuromodulation, and surgery. * Able to communicate sensations during the focused ultrasound treatment * Stable prescribed doses of all symptomatic pain medications for 30 days prior to study entry and for the duration of the 3-month blinded phase of the study. Exclusion Criteria: * Craniofacial pain syndromes related to malignancy of the head and neck * Idiopathic trigeminal neuralgia * Headache syndromes like migraine, cluster headache * Temporomandibular joint syndrome * Atypical facial pain or pain related to a somatoform disorder * Subjects with active psychiatric illness will be excluded. For the purpose of this study, active psychiatric illness includes: * Exhibiting current suicide ideation and/or a history of suicide attempt within past 2 years * been hospitalized for the treatment of a psychiatric illness within the past 2 ye…